Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.

Vishwanathan K, Cantarini M, So K, Masson E, Fetterolf J, Ramalingam SS, Harvey RD.

Clin Transl Sci. 2019 Sep 9. doi: 10.1111/cts.12688. [Epub ahead of print]

PMID:
31498564
2.

Evans Syndrome in Childhood: Long Term Follow-Up and the Evolution in Primary Immunodeficiency or Rheumatological Disease.

Rivalta B, Zama D, Pancaldi G, Facchini E, Cantarini ME, Miniaci A, Prete A, Pession A.

Front Pediatr. 2019 Jul 23;7:304. doi: 10.3389/fped.2019.00304. eCollection 2019.

3.

Synthesis, Characterization and Antioxidant Properties of a New Lipophilic Derivative of Edaravone.

Minnelli C, Laudadio E, Galeazzi R, Rusciano D, Armeni T, Stipa P, Cantarini M, Mobbili G.

Antioxidants (Basel). 2019 Jul 31;8(8). pii: E258. doi: 10.3390/antiox8080258.

4.

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G.

Cancer. 2019 Mar 15;125(6):892-901. doi: 10.1002/cncr.31891. Epub 2018 Dec 4.

PMID:
30512189
5.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H.

Cancer Sci. 2018 Apr;109(4):1177-1184. doi: 10.1111/cas.13511. Epub 2018 Feb 27.

6.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.

Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC.

Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.

PMID:
29293889
7.

Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study.

Zhao H, Cao J, Chang J, Zhang Z, Yang L, Wang J, Cantarini M, Zhang L.

J Clin Pharmacol. 2018 Apr;58(4):504-513. doi: 10.1002/jcph.1042. Epub 2017 Dec 14.

PMID:
29239002
8.

Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.

Tomkinson H, McBride E, Martin P, Lisbon E, Dymond AW, Cantarini M, So K, Holt D.

Clin Ther. 2017 Nov;39(11):2260-2275.e1. doi: 10.1016/j.clinthera.2017.08.022. Epub 2017 Oct 4.

PMID:
28985960
9.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.

Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA.

J Thorac Oncol. 2017 Oct;12(10):1588-1594. doi: 10.1016/j.jtho.2017.07.011. Epub 2017 Jul 24.

10.

EGFR T790M mutation testing within the osimertinib AURA Phase I study.

Dearden S, Brown H, Jenkins S, Thress KS, Cantarini M, Cole R, Ranson M, Jänne PA.

Lung Cancer. 2017 Jul;109:9-13. doi: 10.1016/j.lungcan.2017.04.011. Epub 2017 Apr 19.

PMID:
28577957
11.

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.

Jenkins S, Chih-Hsin Yang J, Jänne PA, Thress KS, Yu K, Hodge R, Weston S, Dearden S, Patel S, Cantarini M, Shepherd FA.

J Thorac Oncol. 2017 Aug;12(8):1247-1256. doi: 10.1016/j.jtho.2017.05.002. Epub 2017 May 17.

12.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.

Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne PA, Mitsudomi T, Goss GD.

J Thorac Oncol. 2017 Jul;12(7):1061-1070. doi: 10.1016/j.jtho.2017.04.003. Epub 2017 Apr 17.

13.

A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients.

Mercuri A, Farruggia P, Timeus F, Lombardi L, Onofrillo D, Putti MC, Pillon M, Cantarini ME, Corti P, Tridello G, De Bortoli M, Pegoraro A, Cesaro S.

Blood Cells Mol Dis. 2017 May;64:45-50. doi: 10.1016/j.bcmd.2017.03.006. Epub 2017 Mar 18.

PMID:
28380398
14.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA.

J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.

15.

Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer.

Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, Cantarini M, Cox E.

Br J Clin Pharmacol. 2017 Jun;83(6):1216-1226. doi: 10.1111/bcp.13223. Epub 2017 Feb 6.

16.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T.

Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.

PMID:
27751847
17.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D.

Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. Epub 2016 Jul 19.

18.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA.

J Clin Oncol. 2016 Oct 1;34(28):3375-82. doi: 10.1200/JCO.2016.66.7162. Epub 2016 Jun 27.

19.

Natural polysaccharides platforms for oral controlled release of ketoprofen lysine salt.

Cerciello A, Auriemma G, Del Gaudio P, Cantarini M, Aquino RP.

Drug Dev Ind Pharm. 2016 Dec;42(12):2063-2069. Epub 2016 Jun 14.

PMID:
27237337
20.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.

Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P.

Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203. Epub 2016 May 25.

PMID:
27226351
21.

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.

Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA.

Cancer Chemother Pharmacol. 2016 Apr;77(4):767-76. doi: 10.1007/s00280-016-2992-z. Epub 2016 Feb 22.

PMID:
26902828
22.

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC.

Lung Cancer. 2015 Dec;90(3):509-15. doi: 10.1016/j.lungcan.2015.10.004. Epub 2015 Oct 9.

23.

Pearson Syndrome: A Retrospective Cohort Study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica).

Farruggia P, Di Cataldo A, Pinto RM, Palmisani E, Macaluso A, Valvo LL, Cantarini ME, Tornesello A, Corti P, Fioredda F, Varotto S, Martire B, Moroni I, Puccio G, Russo G, Dufour C, Pillon M.

JIMD Rep. 2016;26:37-43. doi: 10.1007/8904_2015_470. Epub 2015 Aug 4.

24.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR.

Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.

25.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.

N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.

26.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

27.

Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.

Aung KL, Donald E, Ellison G, Bujac S, Fletcher L, Cantarini M, Brady G, Orr M, Clack G, Ranson M, Dive C, Hughes A.

J Mol Diagn. 2014 May;16(3):343-9. doi: 10.1016/j.jmoldx.2013.12.004. Epub 2014 Mar 12.

PMID:
24631158
28.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR.

Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2.

PMID:
23735514
29.

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.

Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, Cantarini MV, van der Graaf WT, Oyen WJ.

World J Nucl Med. 2012 May;11(2):65-9. doi: 10.4103/1450-1147.103413.

30.

Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients.

Gramenzi A, Tedeschi S, Cantarini MC, Erroi V, Tumietto F, Attard L, Calza L, Foschi FG, Caraceni P, Pavoni M, Cucchetti A, Bernardi M, Viale P, Verucchi G, Trevisani F.

Dig Liver Dis. 2013 Jun;45(6):516-22. doi: 10.1016/j.dld.2012.12.010. Epub 2013 Jan 16.

PMID:
23332770
31.

Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak-like primary immunodeficiency syndrome.

Badolato R, Prandini A, Caracciolo S, Colombo F, Tabellini G, Giacomelli M, Cantarini ME, Pession A, Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Saunders CJ, Zhang L, Schroth GP, Plebani A, Parolini S, Kingsmore SF.

Blood. 2012 Mar 29;119(13):3185-7. doi: 10.1182/blood-2012-01-404350. No abstract available.

PMID:
22461475
32.

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R.

Clin Cancer Res. 2012 Jan 15;18(2):555-67. doi: 10.1158/1078-0432.CCR-11-1491. Epub 2011 Nov 2.

33.

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.

Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H, Twelves C.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1485-95. doi: 10.1007/s00280-011-1611-2. Epub 2011 Apr 13.

PMID:
21487718
34.

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples.

Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G.

J Exp Clin Cancer Res. 2010 Oct 6;29:132. doi: 10.1186/1756-9966-29-132.

35.

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.

Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM.

Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23.

36.

Circulating tumour-derived predictive biomarkers in oncology.

Hodgson DR, Wellings R, Orr MC, McCormack R, Malone M, Board RE, Cantarini MV.

Drug Discov Today. 2010 Feb;15(3-4):98-101. doi: 10.1016/j.drudis.2009.12.006. Epub 2010 Jan 4. Review.

PMID:
20045486
37.

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A.

Br J Cancer. 2009 Nov 17;101(10):1724-30. doi: 10.1038/sj.bjc.6605371. Epub 2009 Oct 27.

38.

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.

Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, Van Der Graaf WT, Van Rossum MM, Van Herpen CM.

Acta Oncol. 2010;49(1):110-3. doi: 10.3109/02841860903104152. No abstract available.

PMID:
19634052
39.

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

Wilson CG, O'Mahony B, Connolly SM, Cantarini MV, Farmer MR, Dickinson PA, Smith RP, Swaisland HC.

Int J Pharm. 2009 Jul 6;376(1-2):7-12. doi: 10.1016/j.ijpharm.2009.04.008. Epub 2009 Apr 14.

PMID:
19497691
40.

Recent advances in the natural history of hepatocellular carcinoma.

Trevisani F, Cantarini MC, Wands JR, Bernardi M.

Carcinogenesis. 2008 Jul;29(7):1299-305. doi: 10.1093/carcin/bgn113. Epub 2008 May 29. Review.

PMID:
18515282
41.

The relative bioavailability of gefitinib administered by granular formulation.

Cantarini MV, Bailey CJ, Collins B, Smith RP.

Cancer Chemother Pharmacol. 2008 Jul;62(2):203-8. Epub 2007 Oct 2.

PMID:
17909808
42.

Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.

Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, Swaisland H, Farmer MR, Cantarini MV, Lennernäs H.

Int J Pharm. 2007 Aug 16;341(1-2):134-42. Epub 2007 Apr 6.

PMID:
17482782
43.

Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal function.

Zambruni A, Trevisani F, Gülberg V, Caraceni P, Domenicali M, Cantarini MC, Cappa FM, Di Micoli A, Magini G, Labate-Morselli AM, Gerbes AL, Bernardi M.

Scand J Gastroenterol. 2007 May;42(5):642-7.

PMID:
17454886
44.

Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance.

Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group.

Am J Gastroenterol. 2007 May;102(5):1022-31. Epub 2007 Feb 21.

PMID:
17313497
45.

Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.

Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR.

Hepatology. 2006 Aug;44(2):446-57.

PMID:
16871543
46.

Pharmacokinetics of two novel bicalutamide formulations in healthy male volunteers.

Cantarini M, Fuhr R, Morris T.

Pharmacology. 2006;77(4):171-8. Epub 2006 Jul 17.

PMID:
16847400
47.

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.

Swaisland HC, Cantarini MV, Fuhr R, Holt A.

Clin Pharmacokinet. 2006;45(6):633-44.

PMID:
16719544
48.

Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.

de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, Lahousse SA, Califano S, Maeda T, Ueno T, D'Errico A, Trevisani F, Wands JR.

J Hepatol. 2006 May;44(5):971-83. Epub 2006 Mar 10.

PMID:
16564107
49.

Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F.

Am J Gastroenterol. 2006 Mar;101(3):524-32.

PMID:
16542289
50.

Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.

Cantarini MC, Trevisani F, Morselli-Labate AM, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M; Italian Liver Cancer (ITA.LI.CA) group.

Am J Gastroenterol. 2006 Jan;101(1):91-8.

PMID:
16405539

Supplemental Content

Loading ...
Support Center